Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9808547rdf:typepubmed:Citationlld:pubmed
pubmed-article:9808547lifeskim:mentionsumls-concept:C0023493lld:lifeskim
pubmed-article:9808547lifeskim:mentionsumls-concept:C0086427lld:lifeskim
pubmed-article:9808547lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:9808547lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:9808547lifeskim:mentionsumls-concept:C1742737lld:lifeskim
pubmed-article:9808547pubmed:issue10lld:pubmed
pubmed-article:9808547pubmed:dateCreated1998-12-21lld:pubmed
pubmed-article:9808547pubmed:abstractTextThe presence of circulating "flower cells" and a low prevalence of antibody to Tax regulatory protein of human T-lymphotropic virus type I (HTLV-I) are characteristics of adult T-cell leukemia (ATL). To examine the predictability of levels of HTLV-I antibodies and of flower cell-like abnormal lymphocytes (Ably) for the risk of ATL among asymptomatic HTLV-I carriers, we prospectively evaluated the levels of viral markers of five HTLV-I carriers who developed ATL and 38 age-, sex-, and screen-matched HTLV-I-positive controls in the Miyazaki Cohort Study. After accounting for matching factors, Ably level was slightly, but not significantly, higher among cases than among controls (P =.13). Anti-HTLV-I (odds ratio [OR] = 1.6 per twofold dilution; 95% confidence interval [CI] 0.94, 3.8) was associated with ATL diagnosis, but antibody to Tax regulatory protein (anti-Tax) was not (OR = 0.78; 95% CI 0.26, 1.7). Anti-Tax level was low for all ATL cases for up to 10 years preceding their diagnosis, independent of the level of anti-HTLV-I titer. HTLV-I carriers with a higher anti-HTLV-I titer and a lower anti-Tax reactivity may be at greatest risk of ATL.lld:pubmed
pubmed-article:9808547pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9808547pubmed:languageenglld:pubmed
pubmed-article:9808547pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9808547pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9808547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9808547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9808547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9808547pubmed:statusMEDLINElld:pubmed
pubmed-article:9808547pubmed:monthNovlld:pubmed
pubmed-article:9808547pubmed:issn0006-4971lld:pubmed
pubmed-article:9808547pubmed:authorpubmed-author:ShioiriSSlld:pubmed
pubmed-article:9808547pubmed:authorpubmed-author:OkayamaAAlld:pubmed
pubmed-article:9808547pubmed:authorpubmed-author:HisadaMMlld:pubmed
pubmed-article:9808547pubmed:authorpubmed-author:MuellerN ENElld:pubmed
pubmed-article:9808547pubmed:authorpubmed-author:StuverS OSOlld:pubmed
pubmed-article:9808547pubmed:authorpubmed-author:SpiegelmanD...lld:pubmed
pubmed-article:9808547pubmed:issnTypePrintlld:pubmed
pubmed-article:9808547pubmed:day15lld:pubmed
pubmed-article:9808547pubmed:volume92lld:pubmed
pubmed-article:9808547pubmed:ownerNLMlld:pubmed
pubmed-article:9808547pubmed:authorsCompleteYlld:pubmed
pubmed-article:9808547pubmed:pagination3557-61lld:pubmed
pubmed-article:9808547pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:meshHeadingpubmed-meshheading:9808547-...lld:pubmed
pubmed-article:9808547pubmed:year1998lld:pubmed
pubmed-article:9808547pubmed:articleTitleRisk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I.lld:pubmed
pubmed-article:9808547pubmed:affiliationDepartments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA, USA. mh280i@nih.govlld:pubmed
pubmed-article:9808547pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9808547pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9808547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9808547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9808547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9808547lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9808547lld:pubmed